company background image
QLGN

Qualigen Therapeutics NasdaqCM:QLGN Stock Report

Last Price

US$0.29

Market Cap

US$11.3m

7D

-8.2%

1Y

-79.9%

Updated

26 Sep, 2022

Data

Company Financials +
QLGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

QLGN Stock Overview

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases.

Qualigen Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Qualigen Therapeutics
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$3.12
52 Week LowUS$0.26
Beta-0.16
1 Month Change-25.26%
3 Month Change-47.84%
1 Year Change-79.90%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.45%

Recent News & Updates

Shareholder Returns

QLGNUS BiotechsUS Market
7D-8.2%-5.3%-6.9%
1Y-79.9%-30.6%-23.7%

Return vs Industry: QLGN underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: QLGN underperformed the US Market which returned -23% over the past year.

Price Volatility

Is QLGN's price volatile compared to industry and market?
QLGN volatility
QLGN Average Weekly Movement4.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: QLGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: QLGN's weekly volatility has decreased from 20% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199643Michael Poirierhttps://www.qualigeninc.com

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.

Qualigen Therapeutics Fundamentals Summary

How do Qualigen Therapeutics's earnings and revenue compare to its market cap?
QLGN fundamental statistics
Market CapUS$11.31m
Earnings (TTM)-US$15.70m
Revenue (TTM)US$4.79m

2.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
QLGN income statement (TTM)
RevenueUS$4.79m
Cost of RevenueUS$10.27m
Gross Profit-US$5.48m
Other ExpensesUS$10.22m
Earnings-US$15.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin-114.50%
Net Profit Margin-327.83%
Debt/Equity Ratio5.1%

How did QLGN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is QLGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QLGN?

Other financial metrics that can be useful for relative valuation.

QLGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does QLGN's PS Ratio compare to its peers?

QLGN PS Ratio vs Peers
The above table shows the PS ratio for QLGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.1x
IMNN Imunon
22.9x83.5%US$11.4m
VBLT Vascular Biogenics
18.4x-35.8%US$10.5m
YBGJ Yubo International Biotech
23.4xn/aUS$10.6m
MYMX Mymetics
11.7xn/aUS$10.3m
QLGN Qualigen Therapeutics
2.4x19.7%US$11.3m

Price-To-Sales vs Peers: QLGN is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (19.1x).


Price to Earnings Ratio vs Industry

How does QLGN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: QLGN is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Biotechs industry average (12.5x)


Price to Sales Ratio vs Fair Ratio

What is QLGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QLGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: QLGN is expensive based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).


Share Price vs Fair Value

What is the Fair Price of QLGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate QLGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate QLGN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Qualigen Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-27.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QLGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QLGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QLGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QLGN's revenue (19.7% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: QLGN's revenue (19.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if QLGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Qualigen Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-34.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: QLGN is currently unprofitable.

Growing Profit Margin: QLGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QLGN is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.

Accelerating Growth: Unable to compare QLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: QLGN has a negative Return on Equity (-85.02%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Qualigen Therapeutics's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: QLGN's short term assets ($13.7M) exceed its short term liabilities ($5.6M).

Long Term Liabilities: QLGN's short term assets ($13.7M) exceed its long term liabilities ($2.2M).


Debt to Equity History and Analysis

Debt Level: QLGN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if QLGN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QLGN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: QLGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 56.5% each year


Discover healthy companies

Dividend

What is Qualigen Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Qualigen Therapeutics Dividend Yield vs Market
How does Qualigen Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Qualigen Therapeutics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Qualigen Therapeutics)n/a

Notable Dividend: Unable to evaluate QLGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QLGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QLGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QLGN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QLGN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Michael Poirier (66 yo)

5.75yrs

Tenure

US$742,279

Compensation

Mr. Michael S. Poirier has been Chief Executive Officer of Qualigen Therapeutics, Inc. (formerly known as Qualigen, Inc.) since December 12, 2016 and served as its President since December 12, 2016 until D...


CEO Compensation Analysis

Michael Poirier's Compensation vs Qualigen Therapeutics Earnings
How has Michael Poirier's remuneration changed compared to Qualigen Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$742kUS$518k

-US$18m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$5mUS$291k

-US$20m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$252kUS$252k

-US$1m

Compensation vs Market: Michael's total compensation ($USD742.28K) is about average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: QLGN's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: QLGN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:QLGN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Jun 22BuyUS$17,100Michael PoirierIndividual30,000US$0.57
14 Jun 22BuyUS$18,600Amy BroidrickIndividual30,000US$0.62

Ownership Breakdown

What is the ownership structure of QLGN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders298,9710.8%
Institutions2,273,8705.9%
General Public36,222,70093.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.8%.


Top Shareholders

Top 25 shareholders own 6.61% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
2.65%
The Vanguard Group, Inc.
1,026,272$299.2k-12.21%no data
0.67%
BlackRock, Inc.
258,419$75.3k-22.79%no data
0.58%
Geode Capital Management, LLC
226,671$66.1k6.61%no data
0.54%
Michael Poirier
210,207$61.3k0%no data
0.33%
T. Rowe Price Group, Inc.
128,900$37.6k0%no data
0.28%
State Street Global Advisors, Inc.
109,314$31.9k3.7%no data
0.23%
Wilcoxson Wealth Management
87,510$25.5k0%no data
0.21%
Highmark Wealth Management LLC
80,094$23.3k0%0.02%
0.14%
Franklin Resources, Inc.
55,448$16.2k-32.38%no data
0.13%
Raymond James Financial Services Advisors, Inc.
48,641$14.2k11.46%no data
0.11%
Northern Trust Global Investments
43,253$12.6k0%no data
0.09%
Bank of America Corporation, Asset Management Arm
35,031$10.2k0%no data
0.089%
Amy Broidrick
34,500$10.1k0%no data
0.083%
Wedbush Asset Management, LLC
32,228$9.4k0%no data
0.071%
Creative Planning, LLC
27,633$8.1k0.09%no data
0.052%
Kestra Advisory Services, LLC
20,000$5.8k0%no data
0.051%
Cra Financial Services L.L.C
19,957$5.8k0%no data
0.051%
Sidney Emery
19,681$5.7k0%no data
0.049%
BNY Mellon Asset Management
18,879$5.5k0%no data
0.047%
Group One Trading LP, Asset Management Arm
18,247$5.3k-29.29%no data
0.046%
Kurt Kruger
18,000$5.2k0%no data
0.04%
Soltis Investment Advisors LLC
15,439$4.5k0%no data
0.032%
Christopher Lotz
12,541$3.7k0%no data
0.024%
Tower Research Capital LLC
9,225$2.7k-31.03%no data
0.021%
U.S. Bancorp Asset Management, Inc.
8,243$2.4k0%no data

Company Information

Qualigen Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Qualigen Therapeutics, Inc.
  • Ticker: QLGN
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.309m
  • Shares outstanding: 38.80m
  • Website: https://www.qualigeninc.com

Number of Employees


Location

  • Qualigen Therapeutics, Inc.
  • 2042 Corte Del Nogal
  • Carlsbad
  • California
  • 92011
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QLGNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2020
7R9BDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.